Dynamic assessment of proliferation to guide response-adapted therapy in the setting of neoadjuvant chemotherapy in ER+/HER2- breast cancer
Hani Saghir(Lund University), Siker Kimbung(Lund University), Srinivas Veerla(Lund University), Niklas Loman(Lund University)
Cited by 0
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
A Molecular Taxonomy for Urothelial Carcinoma
|Clinical Cancer Research|2012|1k
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534